{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:48:59Z","timestamp":1779306539032,"version":"3.51.4"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00186","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T05:48:10Z","timestamp":1584424090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy"],"prefix":"10.3389","volume":"11","author":[{"given":"Peggy S.","family":"Eis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor J.","family":"Koralnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene O.","family":"Major","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina R.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houria","family":"Hendel-Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Gasnault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassine","family":"Taoufik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Hatchwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-pathol-020712-164018","article-title":"Progressive multifocal leukoencephalopathy: why gray and white matter","volume":"8","author":"Gheuens","year":"2013","journal-title":"Annu Rev Pathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ncl.2018.06.002","article-title":"Progressive multifocal leukoencephalopathy","volume":"36","author":"Grebenciucova","year":"2018","journal-title":"Neurol Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-virology-101416-041439","article-title":"Progressive multifocal leukoencephalopathy: endemic viruses and lethal brain disease","volume":"4","author":"Haley","year":"2017","journal-title":"Annu Rev Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00415-016-8217-x","article-title":"Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases","volume":"263","author":"Maas","year":"2016","journal-title":"J Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2232","DOI":"10.1212\/WNL.0000000000007451","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in Germany","volume":"92","author":"Blankenbach","year":"2019","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jnnp-2018-319208","article-title":"Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution","volume":"90","author":"Scarpazza","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fimmu.2018.00138","article-title":"Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird's eye view","volume":"9","author":"Mills","year":"2018","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0961203315622819","article-title":"Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review","volume":"25","author":"Henegar","year":"2016","journal-title":"Lupus."},{"key":"B13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J Neurovirol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e2077","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab","volume":"29","author":"Focosi","year":"2019","journal-title":"Rev Med Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther Adv Neurol Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13311-017-0570-7","article-title":"Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies","volume":"14","author":"Williamson","year":"2017","journal-title":"Neurotherapeutics."},{"key":"B17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/1352458517728814","article-title":"Anti-JCV serology during natalizumab treatment: review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters","volume":"24","author":"Schwab","year":"2018","journal-title":"Mult Scler."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in multiple sclerosis: long-term management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fimmu.2015.00216","article-title":"Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy?","volume":"6","author":"Hatchwell","year":"2015","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10875-014-0116-2","article-title":"Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease","volume":"35","author":"Dhalla","year":"2015","journal-title":"J Clin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fimmu.2016.00220","article-title":"Genetic diagnosis using whole exome sequencing in common variable immunodeficiency","volume":"7","author":"Maffucci","year":"2016","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/cid\/civ1220","article-title":"Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature","volume":"62","author":"Zerbe","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2016.12.013","article-title":"Evaluation of RAG1 mutations in an adult with combined immunodeficiency and progressive multifocal leukoencephalopathy","volume":"179","author":"Schr\u00f6der","year":"2017","journal-title":"Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10875-018-0578-8","article-title":"Progressive multifocal leukoencephalopathy in primary immunodeficiencies","volume":"39","author":"Hadjadj","year":"2019","journal-title":"J Clin Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10875-017-0465-8","article-title":"The 2017 IUIS phenotypic classification for primary immunodeficiencies","volume":"38","author":"Bousfiha","year":"2018","journal-title":"J Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10875-017-0464-9","article-title":"International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity","volume":"38","author":"Picard","year":"2018","journal-title":"J Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10875-014-0114-4","article-title":"Whole genome sequencing reveals a chromosome 9p deletion causing DOCK8 deficiency in an adult diagnosed with hyper IgE syndrome who developed progressive multifocal leukoencephalopathy","volume":"35","author":"Day-Williams","year":"2015","journal-title":"J Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaci.2013.01.052","article-title":"Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis","volume":"131","author":"Sampaio","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/acn3.279","article-title":"Progressive multifocal leukoencephalopathy in an immunocompetent patient","volume":"3","author":"van der Kolk","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1126\/science.1139522","article-title":"TLR3 deficiency in patients with herpes simplex encephalitis","volume":"317","author":"Zhang","year":"2007","journal-title":"Science."},{"key":"B35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev-genet-120116-023425","article-title":"Human genetic determinants of viral diseases","volume":"51","author":"Kenney","year":"2017","journal-title":"Annu Rev Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.coi.2019.03.008","article-title":"Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism","volume":"59","author":"Zhang","year":"2019","journal-title":"Curr Opin Immunol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/531210","article-title":"Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes","author":"Konrad","year":"2019","journal-title":"bioRxiv [Preprint]"},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature."},{"key":"B39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nbt.4235","article-title":"A universal SNP and small-indel variant caller using deep neural networks","volume":"36","author":"Poplin","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics."},{"key":"B42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/humu.22932","article-title":"dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs","volume":"37","author":"Liu","year":"2016","journal-title":"Hum Mutat."},{"key":"B43","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3466","article-title":"Primary antibody deficiencies","volume":"13","author":"Durandy","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nri3493","article-title":"The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases","volume":"13","author":"Milner","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.iac.2015.07.002","article-title":"Severe combined immunodeficiency disorders","volume":"35","author":"Chinn","year":"2015","journal-title":"Immunol Allergy Clin North Am."},{"key":"B47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/gene.2015.3","article-title":"Rare mendelian primary immunodeficiency diseases associated with impaired NF-kappaB signaling","volume":"16","author":"Paciolla","year":"2015","journal-title":"Genes Immun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13223-016-0130-4","article-title":"Primary immunodeficiencies associated with eosinophilia","volume":"12","author":"Navabi","year":"2016","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2018.00636","article-title":"Evaluating the genetics of common variable immunodeficiency: monogenetic model and beyond","volume":"9","author":"de","year":"2018","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41436-018-0012-x","article-title":"Clinical implications of systematic phenotyping and exome sequencing in patients with primary antibody deficiency","volume":"21","author":"Abolhassani","year":"2019","journal-title":"Genet Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri3850","article-title":"Aicardi-Goutieres syndrome and the type I interferonopathies","volume":"15","author":"Crow","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J Exp Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12969-016-0094-4","article-title":"Type I interferonopathies in pediatric rheumatology","volume":"14","author":"Volpi","year":"2016","journal-title":"Pediatr Rheumatol Online J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/eji.201646484","article-title":"Negative regulators of the RIG-I-like receptor signaling pathway","volume":"47","author":"Quicke","year":"2017","journal-title":"Eur J Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41467-017-01932-3","article-title":"Type I interferon-mediated autoinflammation due to DNase II deficiency","volume":"8","author":"Rodero","year":"2017","journal-title":"Nat Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3389\/fimmu.2018.01551","article-title":"Epistatic interactions between mutations of deoxyribonuclease 1-like 3 and the inhibitory Fc gamma receptor IIB result in very early and massive autoantibodies against double-stranded DNA","volume":"9","author":"Weisenburger","year":"2018","journal-title":"Front Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s13238-012-2924-6","article-title":"Complement genetics, deficiencies, and disease associations","volume":"3","author":"Mayilyan","year":"2012","journal-title":"Protein Cell."},{"key":"B60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/jnr.23135","article-title":"Polyomavirus JC infection inhibits differentiation of oligodendrocyte progenitor cells","volume":"91","author":"Darbinyan","year":"2013","journal-title":"J Neurosci Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e110122","DOI":"10.1371\/journal.pone.0110122","article-title":"Rad51 activates polyomavirus JC early transcription","volume":"9","author":"White","year":"2014","journal-title":"PLoS ONE."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e00903","DOI":"10.1128\/mBio.00903-16","article-title":"JC polyomavirus infection of primary human renal epithelial cells is controlled by a type I IFN-induced response","volume":"7","author":"Assetta","year":"2016","journal-title":"mBio."},{"key":"B63","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13365-016-0435-6","article-title":"The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC","volume":"22","author":"Wollebo","year":"2016","journal-title":"J Neurovirol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ana.24987","article-title":"Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy","volume":"82","author":"Fissolo","year":"2017","journal-title":"Ann Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/tpj.2016.34","article-title":"Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies","volume":"17","author":"Tonk","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study","volume":"83","author":"O'Connor","year":"2014","journal-title":"Neurology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s13365-016-0482-z","article-title":"Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV(R) DxSelect antibody assay","volume":"22","author":"Campagnolo","year":"2016","journal-title":"J Neurovirol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","article-title":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Borchardt","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B71","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ajhg.2016.06.031","article-title":"Determinants of power in gene-based burden testing for monogenic disorders","volume":"99","author":"Guo","year":"2016","journal-title":"Am J Hum Genet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e1006481","DOI":"10.1371\/journal.pcbi.1006481","article-title":"How good are pathogenicity predictors in detecting benign variants?","volume":"15","author":"Niroula","year":"2019","journal-title":"PLoS Comput Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis - insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B76","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin Drug Saf."},{"key":"B77","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2015-311100","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B78","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1212\/WNL.0000000000008135","article-title":"Prospective validation of the PML risk biomarkerl-selectin and influence of natalizumab extended intervals","volume":"93","author":"Schwab","year":"2019","journal-title":"Neurology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","article-title":"Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression","volume":"81","author":"Gheuens","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1212\/WNL.0000000000004935","article-title":"Progressive multifocal leukoencephalopathy: are you aware of it?","volume":"90","author":"Clifford","year":"2018","journal-title":"Neurology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/WNL.0000000000004926","article-title":"The national incidence of PML in Sweden, 1988-2013","volume":"90","author":"Iacobaeus","year":"2018","journal-title":"Neurology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1212\/NXI.0000000000000618","article-title":"Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study","volume":"6","author":"Anand","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B83","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1212\/CPJ.0000000000000227","article-title":"Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS","volume":"6","author":"Spelman","year":"2016","journal-title":"Neurol Clin Pract."},{"key":"B84","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11940-019-0592-z","article-title":"Newer treatment approaches in pediatric-onset multiple sclerosis","volume":"21","author":"Macaron","year":"2019","journal-title":"Curr Treat Options Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00415-019-09554-z","article-title":"No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab","volume":"267","author":"Margoni","year":"2020","journal-title":"J Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/CPJ.0000000000000112","article-title":"Multiple sclerosis in US minority populations: clinical practice insights","volume":"5","author":"Khan","year":"2015","journal-title":"Neurol Clin Pract."},{"key":"B87","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ncl.2017.08.007","article-title":"Ethnic considerations and multiple sclerosis disease variability in the United States","volume":"36","author":"Rivas-Rodriguez","year":"2018","journal-title":"Neurol Clin."},{"key":"B88","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11910-019-1000-5","article-title":"Clinical characteristics of multiple sclerosis in African-Americans","volume":"19","author":"Cipriani","year":"2019","journal-title":"Curr Neurol Neurosci Rep."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00186\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T16:51:38Z","timestamp":1584550298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00186\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":88,"alternative-id":["10.3389\/fneur.2020.00186"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00186","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"article-number":"186"}}